Synaptotagmin X Inhibitors
The term Synaptotagmin X Inhibitors refers to a group of chemicals that, while not directly acting on Synaptotagmin X, can influence cellular processes or signaling pathways related to its function. Synaptotagmins, including SytX, are integral to vesicle trafficking, particularly in calcium-triggered vesicle fusion events. Thus, inhibitors within this classification primarily target pathways related to calcium sensing, vesicle transport, and vesicle fusion mechanisms.
For instance, chemicals like BAPTA-AM and Lanthanum act by modulating intracellular calcium levels, which are vital for the calcium-sensing role of synaptotagmins. Other agents, such as Tetanus toxin and Clostridium botulinum toxin B, target the SNARE complex, highlighting the significance of vesicle fusion machinery where synaptotagmin functions. Further, the actin cytoskeleton and myosin-based transport systems are crucial for the movement of vesicles. Agents like Latrunculin A and Blebbistatin underscore the importance of these cellular structures in pathways where synaptotagmin may play a part. In essence, while these chemicals don't target Synaptotagmin X directly, their influence on related cellular processes provides insight into modulatory mechanisms concerning Synaptotagmin X functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore inhibits dynamin, a protein essential for vesicle fission. This can affect vesicle recycling, a step where synaptotagmin functions. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
NEM modifies and inactivates NSF, a protein crucial for SNARE complex disassembly, indirectly affecting synaptotagmin's role. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
This is an IP3 receptor antagonist and can affect calcium release from the ER, potentially impacting synaptotagmin function. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $110.00 $440.00 $660.00 $1200.00 | 2 | |
ML9 is a myosin light chain kinase inhibitor that can influence vesicle trafficking and indirectly affect synaptotagmin-mediated processes. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
This agent disrupts actin filaments, which play roles in vesicle transport. Its effects can alter pathways where synaptotagmin operates. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
By inhibiting myosin II, Blebbistatin can affect vesicle movement and fusion events involving synaptotagmin. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin disrupts vesicular transport by altering intracellular ion concentrations, possibly impacting synaptotagmin-involved pathways. | ||||||